Pfizer Halts Phase 2 Immune Thrombocytopenia Trial as PF-06835375 Faces an Unclear Path
Pfizer has stopped a phase 2 study of PF-06835375, its CXCR5 antibody, in primary immune thrombocytopenia after deciding to terminate the trial for business reasons. The company said the move was not driven by safety concerns, but it stopped short of explaining whether the antibody still has a future in autoimmune disease or whether development has been frozen across the broader program.
The study enrolled 61 patients and began in 2022, placing the asset squarely in the middle of a relatively rare autoimmune blood disorder where platelet counts fall because the immune system targets the body’s own platelets. In ITP, the central clinical problem is not just a low laboratory value; it is the constant tension between bleeding risk and the need for treatment strategies that can raise platelets without exposing patients to unacceptable toxicity or long-term immunosuppression. The decision to stop a midstage trial in that setting often carries as much strategic weight as scientific weight. It tells clinicians and investors alike that the burden of proof for a new mechanism remains high, even when the biology looks appealing on paper.
CXCR5 has attracted interest because of its role in immune-cell trafficking and its relevance to B-cell biology. In autoimmune disease, a target that can interfere with the formation or maintenance of pathogenic B-cell responses can, in theory, alter the immune cascade that drives platelet destruction. That mechanistic logic has made CXCR5 attractive enough to pursue in both autoimmune and oncology settings, especially because expression in normal tissue appears limited. Yet a plausible mechanism does not guarantee clinical success, and the distance between receptor biology and meaningful platelet recovery can be wide.
Pfizer has kept PF-06835375 listed on its pipeline pages for both ITP and lupus, and a phase 1 lupus study completed in 2022. Even so, the company has not clarified whether all development has been abandoned or whether the molecule may still surface in another indication. That uncertainty matters because a program can be truncated for portfolio reasons long before the scientific questions are fully answered. A phase 2 termination does not necessarily mean the biology failed; sometimes it means the corporate calculus changed first.
The practical consequence is straightforward: patients and investigators lose momentum on a trial that might have clarified whether CXCR5 blockade has a place in autoimmune hematology. For a disorder like ITP, where treatment selection often depends on durability of response, tolerability, and the possibility of avoiding chronic steroid exposure, every new mechanism enters a crowded and unforgiving field. Existing therapies already have to compete against a long list of standards and second-line options, so any new candidate must show a clear clinical advantage rather than theoretical novelty.
Pfizer’s decision also lands in a therapeutic area where other drug developers have already faced setbacks. Novartis had explored its B-cell-depleting antibody ianalumab in ITP, but the program struggled to demonstrate benefit in the clinic for that indication. The repeated difficulty in this disease points to a familiar problem in autoimmune hematology: immune pathways that look druggable in preclinical systems do not always translate into durable platelet gains in patients. Heterogeneity in disease mechanisms, variable baseline platelet counts, and differences in prior treatment exposure can all blur the signal in midstage studies.
The current signal around PF-06835375 is not safety. It is uncertainty. Pfizer specifically stated that the trial ended for business reasons, and no safety issue was cited. That leaves the core clinical question untouched: would CXCR5 inhibition have produced enough platelet response, durability, or steroid-sparing benefit to justify a larger program? Without those data, the asset remains suspended between biological rationale and commercial triage.
What makes the situation more notable is the broader context in which CXCR5 sits. The receptor has been studied in blood cancers such as diffuse large B-cell lymphoma and mantle cell lymphoma, where its restricted expression in normal tissue has made it attractive to drug developers. Vincerx Pharma had planned to take an anti-CXCR5 ADC into the clinic for B-cell malignancies before that effort was shelved because of cash constraints. The target still has strategic appeal, but that appeal now appears stronger in theory than in late-stage execution.
For hematologists, the immediate question is not whether CXCR5 is interesting. It is whether the mechanism can survive the unforgiving demands of clinical development in an autoimmune disease where the treatment bar is high and the margin for error is narrow. The next readout, if any, will need to answer whether PF-06835375 can do more than occupy a pipeline slot. Until Pfizer says otherwise, the program’s future remains open to interpretation, and the trial’s early closure leaves a conspicuous gap in the evidence base for CXCR5-directed therapy in ITP.